Supplementary Data — Inhaled Heparin reduces COVID-19 risk: real-time meta-analysis of 3 studies

@CovidAnalysis, October 2026, Version 1V1

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Inhaled heparin COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

DeNucci (DB RCT)42%0.58 · 0.24–1.44death6/3810/37 DeNucci (DB RCT)42%0.58 · 0.24–1.44ventilation6/3810/37 DeNucci (DB RCT)5%0.95 · 0.66–1.37hosp. time38 (n)38 (n) Smith (RCT)−70%1.70 · 0.16–17.60death2/271/23Intubated patients Smith (RCT)15%0.85 · 0.06–12.87death1/271/23Intubated patients van Haren (RCT)58%0.42 · 0.21–0.80death12/18229/186INHALE-HEP van Haren (RCT)71%0.29 · 0.15–0.58death10/23534/238INHALE-HEP van Haren (RCT)47%0.53 · 0.31–0.86ventilation21/23440/235INHALE-HEP van Haren (RCT)23%0.77 · 0.61–0.95hosp.238 (n)240 (n)INHALE-HEP

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Inhaled Heparin
reduces riskInhaled Heparin
increases risk →

Fig. S1. All outcomes.